The Viral Vector Core (VVC) serves as a research facility that supports gene transfer studies. Its overall objective is to support investigators in the use of gene transfer technologies, including consultation with investigators, development of novel vectors, collaborative testing of vectors generated for function and purity, and preparation including quality control. The facility serves both HCCC members and a significant number of investigators from other NCI-designated cancer centers. VVC staff are active participants in the development of gene transfer technologies in the cancer field. The interaction with multiple investigators from various disciplines and institutions allows for cross-fertilization of ideas, technical advancements, and innovations in vector designs. The VVC provides purified and concentrated preparations of recombinant adenovirus, adeno-associated virus, vaccinia, baculovirus and retrovirus (including lentivirus). It also provides access to standard cell lines, expression plasmids and a stock of recombinant reporter viral vectors. The main responsibilities of the VVC are to: prepare recombinant vectors; perform relevant quality control; disseminate vectors; maintain a database of vector stocks available for use; maintain a database of expression vectors; develop new expression vectors as needed; develop novel methods for vector production; and assist in the design and development of novel vectors.